Descovy Approved for HIV Prexposure Prophylaxis

Descovy (a combination of emtricitabine 200 mg and tenofovir alafenamide 25 mg) has been approved for HIV preexposure prophylaxis (PrEP). The drug was previously approved to treat HIV in combination with other antiretroviral drugs. Descovy carries a boxed warning that patients who also have hepatitis B virus (HBV) can experience exacerbations of HBV upon discontinuing Descovy.